Post-Inflammatory Hyperpigmentation (PIH): Treatment Guide 2026

What Is PIH? Definition and Epidemiology

Post-inflammatory hyperpigmentation (PIH) is the regional darkening of the skin following any inflammatory or traumatic event. The primary mechanism involves increased accumulation of melanin in the epidermis and/or dermis in response to inflammation. While PIH can affect individuals of all ages and skin types, its incidence is markedly higher in those with Fitzpatrick scale type III and above.

Globally, PIH remains one of the most common reasons for dermatology consultations among darker-skinned populations. According to a large-scale study published in the International Journal of Dermatology (2019), the lifetime prevalence of PIH in Fitzpatrick type IV–VI individuals is estimated at 65–80%. In Turkey, the prevalence of Fitzpatrick types III–IV is high due to Mediterranean and Middle Eastern genotypes, making PIH a significant medical aesthetic concern in the country. At Virtuana Clinic in Izmit/Kocaeli, post-acne PIH is consistently among the most common pigmentation complaints from patients.

Biochemical Pathogenesis of PIH: The Melanin Production Cascade

Understanding the molecular basis of PIH is critical for identifying the correct treatment target. The inflammatory process triggers the following biochemical cascade:

• Arachidonic acid metabolites: Prostaglandin E2 and leukotrienes released during inflammation directly enhance melanocyte stimulation via the cAMP pathway.
• Reactive oxygen species (ROS): Oxidative stress accelerates melanin synthesis from L-DOPA by increasing tyrosinase enzyme activity.
• SCF/c-Kit signalling: Stem cell factor (SCF) and its receptor c-Kit amplify melanocyte proliferation and migration signals.
• α-MSH and ACTH: Their post-inflammatory elevation activates the MC1R receptor, sustaining melanogenesis.

Acetylation polymorphism, tyrosinase enzyme activity, and the duration of inflammation are the main genetic and environmental factors that determine PIH severity. VEGF (vascular endothelial growth factor) and SCF elevation are also among the cytokines that intensify pigmentation.

Epidermal and Dermal PIH: Two Distinct Presentations

PIH develops at two different depth levels, and the clinical appearance and treatment response of each differ significantly:

• Epidermal PIH: Melanin synthesis increases in response to inflammation and is transported to the epidermis via keratinocytes, producing brown-to-dark-brown tones. It becomes more distinct under Wood's lamp examination. Treatment response is good; marked improvement is expected within an average of 3–6 months.
• Dermal PIH (melanosis): When the basement membrane at the dermo-epidermal junction is damaged, melanin granules "drop" into the dermis and are phagocytosed by macrophages (melanophages). These lesions appear in blue-grey to grey-brown tones and are more resistant to treatment. Resolution may take 6–18 months or longer.

Clinical Classification of PIH Types

Type	Location	Clinical Colour	Wood's Lamp	Treatment Response
Epidermal PIH	Epidermis	Light to dark brown	Accentuated	Good – 3–6 months
Dermal PIH (melanosis)	Dermis	Blue-grey, grey-brown	No response	Moderate – 6–18 months
Mixed	Both layers	Brown with blue tint	Partially accentuated	Variable – 6–24 months

Post-Acne PIH: The Most Common Trigger

Acne vulgaris is the most common trigger of PIH worldwide. Spots that are squeezed or popped — especially inflamed papules — create significant micro-inflammation in the epidermis, making melanocyte activation inevitable. The red-pink discolouration that remains after acne resolves is a temporary post-inflammatory erythema, whereas dark-brown or blackish marks constitute true PIH. Distinguishing between these two presentations is important for treatment selection: erythema resolves spontaneously over time, while PIH requires active treatment.

Other conditions that can trigger PIH include atopic dermatitis, contact dermatitis, impetigo, chickenpox scars, surgical incisions, and aggressive dermatological procedures (incorrectly applied laser or chemical peels). In clinical evaluations at Virtuana Clinic in Izmit/Kocaeli, the majority of PIH presentations are in individuals aged 18–35 with Fitzpatrick type III–IV skin. In this group, early intervention is crucial for preventing permanent pigmentation.

Diagnostic Tools: Wood's Lamp, Dermoscopy, and Reflectance Confocal Microscopy

Correct use of clinical diagnostic tools guides the identification of PIH depth and type:

• Wood's lamp (365 nm UV): Epidermal melanin is accentuated while dermal melanin does not respond. This simple test is the first step in determining PIH depth.
• Dermoscopy: Pigment network structure, granule distribution, and vascular patterns are assessed to differentiate PIH from other pigmentation disorders.
• Reflectance confocal microscopy (RCM): Melanocyte density and dermal melanophage accumulation can be imaged non-invasively; particularly valuable in differentiating melasma from PIH.

At Virtuana Clinic, every pigmentation assessment begins with Wood's lamp and dermoscopy, enabling the treatment protocol to be tailored to individual findings while avoiding unnecessarily aggressive interventions.

Topical Treatment Options: Evidence-Based Comparison

Agent	Mechanism of Action	Evidence Level	Side-Effect Risk	Pregnancy
Azelaic Acid 15–20%	Tyrosinase inhibition, anti-inflammatory, antimicrobial	High (IA)	Low	Safe (B)
Niacinamide 4–10%	Blocks melanosome transfer to keratinocytes	High (IB)	Very low	Safe
Tranexamic Acid 3–5%	Plasminogen activator inhibition, prostaglandin suppression	Moderate–High (IIB)	Low	Use with caution
Alpha-Arbutin 1–2%	Tyrosinase inhibition (hydroquinone precursor)	Moderate (IIB)	Low	Use with caution
Kojic Acid 1–4%	Copper chelation, tyrosinase Cu++ inhibition	Moderate (IIB)	Moderate – contact dermatitis risk	Limited data
Retinoids (tretinoin, adapalene)	Accelerates cell turnover, inhibits melanosome transfer	High (IA)	Moderate – irritation, photosensitivity	Contraindicated
Hydroquinone 2–4%	Tyrosinase inhibition + melanocyte cytotoxicity	High (IA)	High – ochronosis with prolonged use	Contraindicated

At Virtuana Clinic, the primary choice for PIH treatment is a combination of azelaic acid and niacinamide. These two agents act synergistically, carry a very low irritation risk, and can be safely used during pregnancy. In resistant cases, tranexamic acid and alpha-arbutin are added to the protocol, and short-term retinoid support is planned when indicated.

Chemical Peels: Acid Selection and Protocol

Chemical peels are a powerful clinical tool that accelerates topical care in PIH treatment. Correct determination of acid type and concentration directly influences outcomes:

Peeling Acid	Concentration	Depth	Dark Skin Suitability	Specific Indication
Glycolic Acid (AHA)	20–50%	Superficial	Good	Epidermal PIH, all types
Salicylic Acid (BHA)	15–30%	Superficial	Good	Acne + PIH combination
Mandelic Acid	30–40%	Superficial (slow)	Excellent (FP IV–VI)	Darker skin tones, sensitive skin
Lactic Acid	20–40%	Superficial	Good	Moisturising + brightening
TCA (Trichloroacetic Acid)	10–25%	Medium depth	Caution (FP ≤III)	Dermal PIH, resistant cases

In individuals with darker skin tones, the risk of post-peel PIH (paradoxical darkening) must be considered; a pre-conditioning protocol is therefore mandatory before each session: 4–6 weeks of depigmenting topical therapy (azelaic acid or niacinamide) prepares the skin to withstand the stress of peeling.

Laser Treatment: Which Laser, When?

Laser treatment is preferred particularly for resistant and dermal PIH cases. Since incorrect laser selection can worsen darkening, it must be performed by experienced practitioners using appropriate devices.

Laser Type	Wavelength	Indication	Dark Skin Safety	Typical Sessions
Q-switched Nd:YAG	1064 nm	Dermal + epidermal PIH	High	4–6 sessions, every 3–4 weeks
Picosecond Nd:YAG	1064/532 nm	Resistant, mixed PIH	High	3–5 sessions, every 4 weeks
Fractional CO2 (low energy)	10,600 nm	Acne scarring + PIH combination	Moderate – pre-treatment required	2–3 sessions, every 6–8 weeks
IPL (Intense Pulsed Light)	500–1200 nm	Epidermal PIH, lighter skin	Low – contraindicated in FP IV+	3–5 sessions, every 3–4 weeks

At Virtuana Clinic, Q-switched and picosecond laser protocols are safely applied across a wide range of skin tones, including darker complexions. Before each laser session, energy parameters are personalised according to skin type and lesion characterisation; post-laser application of SPF 50+ for 48 hours and restriction of UV exposure to the treated area are required.

Microdermabrasion, Mesotherapy, and Glutathione

Microdermabrasion involves the physical removal of superficial epidermal cells; it can be used once monthly to accelerate topical treatment in mild-to-moderate epidermal PIH. Its efficacy as a standalone treatment is limited; however, it is valuable for enhancing the penetration of topical depigmenting agents.

In mesotherapy protocols, combinations containing tranexamic acid (4–5%), glutathione (600–1200 mg), vitamin C, and rutin are delivered directly to the dermis to deepen melanin inhibition. Intravenous high-dose glutathione has been used in some clinics for systemic brightening; however, topical targeting via oral administration or mesotherapy represents a safer and more evidence-based approach.

Sunscreen: The Indispensable Foundation of Treatment

The most critical component of PIH treatment is sun protection. A broad-spectrum SPF 50+ sunscreen (UVA/UVB) should be applied every morning and reapplied every 2–3 hours on sunny days. Since UV radiation directly triggers melanocyte activation, all treatments become ineffective without consistent sunscreen use.

In individuals with darker skin tones (Fitzpatrick IV–VI), physical filters (zinc oxide, titanium dioxide) are better tolerated than chemical filters and appear superior as they provide protection against both UVA/UVB and visible light. Research shows that visible light can also trigger melanocyte activation, and high-energy visible (HEV) blue light in particular may increase PIH risk in darker skin tones.

Combination Strategies in PIH Treatment: Evidence Summary

Combination	Indication	Expected Improvement	Duration
Azelaic Acid + Niacinamide	Mild–moderate epidermal PIH	40–60%	3–4 months
Topical + Chemical Peel	Moderate epidermal PIH	55–70%	3–5 months
Topical + Q-switched Laser	Dermal or resistant PIH	60–75%	4–8 months
Topical + Mesotherapy	Widespread, moderate-to-deep PIH	50–65%	3–6 months
Triple Combination (Kligman Formula)	Severe, resistant PIH	70–85%	8–16 weeks (short-term)

Prevention Strategies for PIH

• Never squeeze or pop spots; the longer inflammation persists, the greater the risk of PIH.
• Begin active acne treatment without delay; breaking inflammation early is the most effective way to prevent PIH.
• Minimise repeated sun exposure throughout the day; a combination of SPF 50+ physical-filter sunscreen, a hat, and shade is essential.
• Avoid harsh scrubbing and aggressive cleansers on the skin; barrier damage activates melanocytes and increases PIH risk.
• A skincare routine containing niacinamide or azelaic acid can be started prophylactically in high-risk individuals (darker skin tone + active acne).
• After cosmetic procedures (laser, chemical peel, microneedling), follow post-procedure care instructions fully.

Who Is a Candidate for PIH Treatment? Contraindications

PIH treatment can be applied to any adult who has developed dark spots following acne, eczema, allergic reactions, or cosmetic procedures. During pregnancy and breastfeeding, the choice of topical agents is restricted (azelaic acid and niacinamide are preferred; hydroquinone and tretinoin are contraindicated). Active skin infections and known agent allergies require assessment before treatment.

Contraindications include: active herpetic infection (for laser), bleeding disorders (for mesotherapy), pregnancy (retinoids, hydroquinone, aggressive peels), and acute phases of autoimmune skin diseases. The safest and most effective protocol is determined individually for each patient through comprehensive skin analysis.

PIH Treatment Protocol at Virtuana Clinic

At Virtuana Clinic in Izmit/Kocaeli, we manage PIH treatment through a four-stage approach: (1) determination of PIH depth and type using Wood's lamp and dermoscopy; (2) initiation of a topical protocol tailored to skin type and lesion characteristics; (3) planning of supportive in-clinic procedures (peel, Q-switched laser, or mesotherapy); and (4) monitoring treatment efficacy through sun protection guidance, follow-up, and periodic standardised photography. All patient assessments are documented, and treatment response is measured using standardised clinical photographs taken at months 3 and 6 under controlled lighting conditions.

This comprehensive approach, offered to patients from Kocaeli, Gebze, Körfez, Izmit, and surrounding areas, delivers high satisfaction and safety rates in PIH management. Personalised plans are developed particularly for post-pregnancy hyperpigmentation and combined acne-scar presentations.

Frequently Asked Questions

Is PIH permanent? Epidermal PIH is largely transient; with appropriate treatment, marked improvement is typically seen within 3–6 months. Dermal PIH (melanosis) may persist for 12–18 months. Cases left untreated or unprotected from the sun can become permanent over years.

Should I use hydroquinone? Hydroquinone is an effective agent; however, it carries a risk of exogenous ochronosis with long-term use. At Virtuana Clinic, hydroquinone is used short-term (maximum 8–12 weeks) under dermatologist supervision only when safer alternatives prove insufficient, after which maintenance therapy is initiated.

How long does treatment take? An average of 3–6 months of topical therapy is required; when combined with in-clinic sessions, this timeline can be shortened. Patience, sun protection, and adherence to treatment are the most decisive variables.

What should I do if my skin darkens after a chemical peel? In this paradoxical PIH scenario, the peel should be discontinued, intensive sun protection initiated immediately, and azelaic-acid-based topical therapy started without delay. The next peel session should be postponed by at least 6–8 weeks.

This article is for informational purposes only. Please consult a qualified physician for treatment decisions.